FDA Generic Biologics Short-Term Plan Includes Immunogenicity Document

Immunogenicity and chemistry of follow-on biologics will be among the first issues FDA tackles in documents issued on the topic, Acting Commissioner Lester Crawford said at the Generic Pharmaceutical Association's annual meeting in Boca Raton, Fla